Last updated on April 2020

TPST-1120 as Monotherapy and in Combination With (Nivolumab Docetaxel or Cetuximab) in Subjects With Advanced Cancers


Brief description of study

This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPAR (peroxisome proliferator activated receptor alpha) as monotherapy and in combination with other systemic anticancer agents including nivolumab, an anti-PD1 antibody, docetaxel, a cytotoxic chemotherapeutic agent and cetuximab, an anti-EGFR antibody in subjects with advanced solid tumors.

Detailed Study Description

This is a phase 1/1b open label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of TPST-1120, a small molecule selective antagonist of PPAR (peroxisome proliferator activated receptor alpha) in adult subjects with selected advanced solid tumors. TPST will be administered as monotherapy and in combination with standard of care systemic anticancer agents including nivolumab, an anti-PD1 antibody, docetaxel, a cytotoxic chemotherapeutic agent and cetuximab, an anti-EGFR antibody in subjects with advanced solid tumors. This trial is composed of dose escalation and dose expansion cohorts.

Clinical Study Identifier: NCT03829436

Find a site near you

Start Over

Carolina BioOncology Institute

Huntersville, NC United States
  Connect »

UPMC Hillman Cancer Center

Pittsburgh, PA United States
  Connect »

Stephenson Cancer Center

Oklahoma City, OK United States
  Connect »